AbbVie and Iambic team up on AI small-molecule drug discovery

AbbVie and AI drug company Iambic announced a multi-year collaboration to use Iambic’s molecular-superintelligence platform — including Enchant v3 and NeuralPLexer — to speed small-molecule discovery across immunology, neuroscience, and oncology, with an upfront payment plus milestones and tiered royalties for Iambic and no dollar amounts disclosed.

HEALTH desk — a major pharma is wiring a purpose-built AI discovery model into its core small-molecule hunt. That is AI moving from demo slides into the molecules that might become medicines.

Focus areas, still the companies: immunology, neuroscience, and oncology. First-in-class here means a medicine that works in a new way. Best-in-class means a medicine that aims to beat existing drugs of the same type. File those three disease areas and the first-in-class / best-in-class wording as the companies’. This desk did not name a drug candidate, a target, or a trial. None was printed.

Platform named: Iambic’s molecular superintelligence, powered by Enchant and NeuralPLexer — technologies the release says are designed to optimize many candidate properties at once instead of checking them one by one. The collaboration will use Enchant v3, Iambic’s next-generation multimodal transformer, trained on over 6,000 molecular properties. A multimodal transformer here is a model that reads several kinds of biomedical data at once. File Enchant / NeuralPLexer / Enchant v3 / over-6,000-properties as the companies’. Do not import extra model-size figures from the same-day Enchant v3 launch. That launch is a separate ticket.

Economics, still the companies: Iambic will receive an upfront payment and is eligible for success-based milestone payments and tiered royalties on net sales from products generated from the collaboration. A milestone is an extra payment when a program hits a goal. A royalty is a share of later sales. Specific dollar amounts were not disclosed. File the upfront / milestone / royalty picture as the companies’. This desk is not inventing a deal value, a valuation, or an ownership split.

Named voice on the release: Nicholas Donoghoe, M.D., executive vice president and chief business and strategy officer at AbbVie. He says Iambic is bringing purpose-built AI capabilities to AbbVie’s Discovery scientists, and that fit-for-purpose AI solutions can accelerate discovery and expand what is possible in R&D. File the name, title, and that purpose-built / accelerate-discovery line as his, via the companies. His other sentences stay in Sources.

Named voice, still the same page: Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research at AbbVie. He says combining Iambic’s platform with AbbVie scientists’ drug-hunting expertise can help them make more precise decisions about the molecules they pursue, and that the goal is to design better molecules more efficiently and improve the probability of success. File the name, title, and that more-precise / better-molecules line as his, via the companies. His other sentences stay in Sources.

Named voice, still the same page: Tom Miller, Ph.D., co-founder and CEO of Iambic. He says Iambic’s mission is to make better technology for better medicines — in its own hands and with partners — and that Iambic is eager to bring its molecular-superintelligence platform alongside AbbVie’s team to address unmet patient need. File the name, title, and that better-technology / unmet-need line as his, via the companies. His other sentences stay in Sources.

Plain English for the rest of the card: small molecule = a traditional pill-type drug, not a large biologic shot. milestone = an extra payment when a program hits a goal. royalty / tiered royalties = a share of later sales, with the share changing by band. first-in-class = a medicine that works in a new way. best-in-class = a medicine that aims to beat existing drugs of the same type. molecular superintelligence = Iambic’s name for its AI discovery stack. Enchant v3 = the named model this deal will use, trained on over 6,000 molecular properties. NeuralPLexer = the other named piece of that stack. multimodal transformer = a model that reads several kinds of biomedical data at once. This filing is the partnership announce. It is not a new drug approval and not a priced deal.

PRIMARY here: Iambic’s 21 Sep 2026 company post — Tier A PRIMARY company source, the original record — plus the same-day AbbVie / PR Newswire joint release at 08:00 ET, also Tier A PRIMARY. The multi-year collaboration, the immunology / neuroscience / oncology focus, the first-in-class and best-in-class wording, Enchant and NeuralPLexer, Enchant v3 trained on over 6,000 molecular properties, the undisclosed upfront plus milestones and tiered royalties, and the Donoghoe / Sedgwick / Miller titles and attributed lines are company-attributed. NOT claimed: a dollar size, a valuation, named drug candidates, clinical trial results, that this desk saw a term sheet, a stock tip, or investment advice. Distinct from the already-filed novo-anthropic-claude-drug-discovery, inductive-bio-indy-chemistry, and angle-health-600m-series-c. Distinct from the same-day Enchant v3 model launch — companion, not this deal card.